Skip to main content

Table 1 Baseline and therapeutic characteristics of patients before and after PSM

From: Real-world outcomes of PD-L1 inhibitors combined with thoracic radiotherapy in the first-line treatment of extensive stage small cell lung cancer

Characteristics

Before matching

After matching

With TRT

(n = 70) (%)

Wihout TRT

(n = 141) (%)

p value

With TRT

(n = 57) (%)

Wihout TRT

(n = 57) (%)

p value

Age, median (IQR), yr

61 (54–67)

63 (56–68)

0.237

63 (56–69)

61 (55–66)

0.735

 < 65

45 (64.3)

88 (62.4)

0.791

33 (57.9)

38 (66.7)

0.334

 ≥ 65

25 (35.7)

53 (37.6)

 

24 (42.1)

19 (33.3)

 

Gender

  

0.078

  

0.826

 Male

52 (74.3)

119 (84.4)

 

43 (75.4)

44 (77.2)

 

 Female

18 (25.7)

22 (15.6)

 

14 (24.6)

13 (22.8)

 

ECOG PS

  

0.196

  

0.242

 0–1

64 (91.4)

120 (85.1)

 

52 (91.2)

55 (96.5)

 

 ≥ 2

6 (8.6)

21 (14.9)

 

5 (8.8)

2 (3.5)

 

Weight loss

  

0.219

  

0.281

 Yes

14 (20.0)

19 (13.5)

 

10 (17.5)

6 (10.5)

 

 No

56 (80.0)

122 (86.5)

 

47 (82.5)

51 (89.5)

 

Smoking status

  

0.669

  

0.729

 Never

27 (38.6)

46 (32.6)

 

21 (36.8)

17 (29.8)

 

 Former

21 (30.0)

44 (31.2)

 

19 (33.3)

21 (36.8)

 

 Current

22 (31.4)

51 (36.2)

 

17 (29.8)

19 (33.3)

 

Brain metastases

  

0.384

  

0.528

 Yes

15 (21.4)

38 (27.0)

 

14 (24.6)

17 (29.8)

 

 No

55 (78.6)

103 (73.0)

 

43 (75.4)

40 (70.2)

 

Liver metastases

  

0.032

  

0.528

 Yes

16 (22.9)

53 (37.6)

 

14 (24.6)

17 (29.8)

 

 No

54 (77.1)

88 (62.4)

 

43 (75.4)

40 (70.2)

 

Number of metastases

  

0.026

  

0.192

 < 3

59 (84.3)

99 (70.2)

 

46 (80.7)

40 (70.2)

 

 ≥ 3

11 (15.7)

42 (29.8)

 

11 (19.3)

17 (29.8)

 

Immunotherapy regimens

  

0.809

  

0.341

 Durvalumab

46 (65.7)

95 (67.4)

 

36 (63.2)

31 (54.4)

 

 Atezolizumab

24 (34.3)

46 (32.6)

 

21 (36.8)

26 (45.6)

 

Cycles of immunotherapy

  

0.031

  

0.687

 < 6

20 (28.6)

62 (44.0)

 

17 (29.8)

19 (33.3)

 

 ≥ 6

50 (71.4)

79 (56.0)

 

40 (70.2)

38 (66.7)

 

Chemotherapy regimens

  

0.179

  

0.559

 Etoposide + cisplatin

36 (51.4)

57 (40.4)

 

26 (45.6)

29 (50.9)

 

 Etoposide + carboplatin

28 (40.0)

61 (43.3)

 

25 (43.9)

25 (43.9)

 

 Others

6 (8.6)

23 (16.3)

 

6 (10.5)

3 (5.3)

 

TRT sequence

 

–

  

–

 Sequential

47 (67.1)

–

 

42 (73.7)

–

 

 Concurrent

23 (32.9)

–

 

15 (26.3)

–

 
  1. PSM, propensity score matching; TRT, thoracic radiotherapy; IQR, interquartile range; yr, years; ECOG PS, Eastern Cooperative Oncology Group performance status
Back to article page

Radiation Oncology

ISSN: 1748-717X

Contact us